Peeling Back Hospitals' 340B Rx Scheme to Gouge Employers
April 8, 2025 | 12:00 PM CT
What is 340B?
The 340B program allows hospitals to buy medications at deep discounts and sell them at higher rates, profiting at the expense of Texas employers and employees. There is no assurance these profits benefit vulnerable patients, while the program drives up costs through steep markups, lost rebates, health system consolidation, and incentives for prescribing higher-cost drugs over biosimilars. In some estimations, employers are losing millions of dollars through this program.
To raise awareness of this issue, DFW Business Group on Health, Houston Business Coalition on Health, and the National Alliance has launched an initiative that aims to enhance understanding of the 340B program effects on plan sponsors among our members, other stakeholders, and policymakers.
We are pleased to invite you to a complimentary, employer-focused webinar providing an in-depth exploration of the 340B drug pricing program. This session will focus on the program's impact on employers and working families in Texas. Shawn Gremminger, CEO of the National Alliance of Healthcare Purchaser Coalitions, will offer valuable insights on the current landscape of the 340B program, highlighting the key challenges and potential areas for reform .
Webinar Details
What You’ll Learn:
We encourage you to attend this important discussion and share the invitation with others in your organization who may benefit.
Additional 340B Resources: Below are resources we’ve gathered that provide background on the 340B program and its relevance to Texas employers.